2020 Clinical Trials Data Epilepsy 
Project CBD
MARCH 21, 2023
I nterestingly, and perhaps unfortunately for patients, previous reviews in 2020 and 2019 2 also concluded there was insufficient evidence that cannabis can diminish chronic tinnitus. Cannabinoid Receptors Influence Hearing Finally, a November 2020 review in Frontiers in Neurology 6 adds more complexity and subtlety to the issue.
Veriheal
AUGUST 31, 2020
It brings us great pleasure to present the 10 winners of Veriheal’s Innovation in Cannabis Scholarship 2020. Veriheal’s Innovation in Cannabis Scholarship 2020 Winners . Essay: “Crowdsourcing User Experience Data for a Targeted Medical Cannabis Journey with Cannamunity” . Nishtha Tripathi. School: George Washington University.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Project CBD
FEBRUARY 28, 2023
HerbalGram, the acclaimed quarterly journal of the American Botanical Council, recently published its 2021 “Herb Market Report,” which included data on sales of CBD as an herbal ingredient in mainstream and natural retail channels in the United States. This was somewhat less than the nearly 37% decline seen in 2020.
Cannabis Law Report
JANUARY 10, 2022
This high share is attributable to the rising adoption of THCV for various applications such as epilepsy, arthritis, metabolic disorders, neurological disorders, and pain management. In 2020, based on application, the others segment accounted for the largest revenue share. List To Data Sources. Market Segmentation and Scope.
Cannabis Law Report
DECEMBER 7, 2021
The search included studies through 11-May-2020. This trend is also observed in the pediatric population, where MCs are authorized in children for refractory epilepsy, especially in Dravet syndrome and Lennox-Gastaut syndrome 2. The search included published and unpublished studies through 11-May-2020.
Cannabis Law Report
JANUARY 13, 2020
12, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020. Key Priorities for 2020.
Canna Care Docs
DECEMBER 16, 2020
Between the pandemic and the political climate, 2020 hasn’t exactly been a walk in the park. Although the data is still growing, small studies and anecdotal evidence seem promising for medical marijuana as treatment for psychiatric disorders like depression, anxiety and PTSD. Chronic pain.
Expert insights. Personalized for you.
144 
Let's personalize your content